HeartBeam Inc. (NASDAQ: BEAT), a medical technology company focused on cardiac care innovation, announced it will host a conference call on May 13, 2026, at 4:30 p.m. Eastern time to discuss its first-quarter financial results for the period ended March 31, 2026. The company will also provide updates on key growth initiatives, including its limited commercial launch for arrhythmia assessment, extended-wear patch development, heart attack detection, and artificial intelligence programs.
The announcement is significant as it marks HeartBeam's first earnings call since receiving FDA clearance for its 12-lead ECG synthesis software in December 2025, which builds on the December 2024 clearance for arrhythmia assessment. These clearances position the company to commercialize the first-ever cable-free device capable of collecting ECG signals in 3D from three non-coplanar directions and synthesizing them into a standard 12-lead ECG. This platform technology is designed for portable devices that can be used wherever the patient is, enabling physicians to identify cardiac health trends and acute conditions and direct patients to appropriate care outside of medical facilities.
HeartBeam's technology aims to redefine cardiac health management by delivering actionable heart intelligence. The company holds over 20 issued patents related to its technology. Investors and industry observers will be closely watching the call for details on the commercial launch progress, patient adoption, and reimbursement strategies. The extended-wear patch development and AI programs are also expected to be key topics, as they represent the next phase of the company's product pipeline.
The conference call will be accessible via webcast on the company's investor relations website. A replay will be available afterward. For more information about HeartBeam and its cleared indications for use, visit the company's indications page. The latest news and updates regarding HeartBeam are available in the company's newsroom.
This earnings call comes at a pivotal time for HeartBeam as it transitions from a development-stage company to a commercial-stage entity. The successful limited commercial launch could pave the way for broader market adoption and revenue growth. The extended-wear patch, which aims to provide longer-term monitoring, and AI-driven analytics for heart attack detection, represent significant opportunities for the company to expand its addressable market and improve patient outcomes.
